Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.
Dapansutrile,一种口服选择性 NLRP3 炎症小体抑制剂,用于治疗痛风发作:一项开放标签、剂量适应性、概念验证的 2a 期试验
期刊:Lancet Rheumatology
影响因子:16.400
doi:10.1016/s2665-9913(20)30065-5
Klück Viola, Jansen Tim L Th A, Janssen Matthijs, Comarniceanu Antoaneta, Efdé Monique, Tengesdal Isak W, Schraa Kiki, Cleophas Maartje C P, Scribner Curtis L, Skouras Damaris B, Marchetti Carlo, Dinarello Charles A, Joosten Leo A B